NEW
YORK, July 11, 2024 /PRNewswire/ -- The global
head and neck cancer treatment market size is estimated to grow by
USD 7.12 billion from 2024-2028, at a
CAGR of 13.64%, according to Technavio. Increasing incidence of
head and neck cancers is driving market growth, with a trend
towards technological advancements in diagnosis and treatment.
However, the high cost of treatment poses a challenge. North America and Asia-Pacific are showing the fastest growth in
the market. Key players include Amgen Inc., AstraZeneca Plc, Ayala
Pharmaceuticals Inc., Bristol Myers Squibb Co., and others.
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Head and Neck Cancer
Treatment Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
13.64%
|
Market growth
2024-2028
|
USD 7120.5
million
|
Market
structure
|
Concentrated
|
YoY growth 2022-2023
(%)
|
11.73
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
46%
|
Key
countries
|
US, China, Germany, UK,
and Japan
|
Key companies
profiled
|
Amgen Inc., AstraZeneca
Plc, Ayala Pharmaceuticals Inc., Bristol Myers Squibb Co.,
Debiopharm International SA, Eli Lilly and Co., Incyte Corp., Merck
and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA
|
Market Driver
The head and neck cancer treatment market has experienced
notable advancements in diagnostics and therapies, leading to
improved patient outcomes and personalized care. Technological
innovations, such as PET-CT and MRI imaging, enable early detection
and precise tumor localization. Biomarkers, like HPV DNA and EGFR
mutations, aid in accurate diagnosis and treatment planning.
Robotic surgery offers minimally invasive tumor removal with
minimal tissue damage and faster recovery. Targeted therapies, such
as monoclonal antibodies, specifically target cancer cells and
improve patient survival rates with reduced side effects. These
advancements are driving the growth of the global head and neck
cancer treatment market.
The Head and Neck Cancer Treatment Market is witnessing
significant growth due to the rising incidence of malignant tumors
in the throat, nose, mouth, salivary glands, and larynx. Major
causes include alcohol and tobacco consumption, drugs, and
malignant cells that suppress the immune system. The
Biopharmaceutical industry is responding with new pipeline drugs
like Atezolizumab, Afatinib, and Ipilimumab. Immunotherapy and
targeted therapy are trending treatments, with non-surgical
procedures gaining popularity. Diagnostic tools are essential for
early detection, and cancer awareness campaigns are increasing
healthcare expenditure. Sales channels include online pharmacies
and retail pharmacies via the internet. Systemic drug therapies,
such as Capecitabine, Cetuximab, Paclitaxel, Bleomycin,
Hydroxyurea, and Docetaxel, are common treatment types. Surgical
treatment and combination therapies, like radiation therapy and
combination therapies, are also used. Smoking is a leading risk
factor, with an estimated 50,000 head and neck cancer cases
annually, resulting in numerous outpatient visits.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
- The global head and neck cancer treatment market faces a
significant challenge due to the high cost of treatment. Diagnostic
tests, such as PET scans, biopsies, CT scans, and MRI scans, add
substantial expenses. Specialized medications and therapies,
including chemotherapy, targeted therapies, and immunotherapy
drugs, are expensive, with prices ranging from hundreds to
thousands of dollars per dose. Surgical interventions, like tumor
resection and neck dissection, require specialized equipment and
skilled surgeons, leading to high costs. Reconstructive surgeries
and supportive care, including rehabilitation services, speech
therapy, and nutritional support, further add to the overall
treatment expenses. These factors may hinder market growth during
the forecast period, as patients and their families face
significant financial strain.
- The Head and Neck Cancer Treatment Market faces challenges in
the form of limited treatment options and significant side effects
from existing therapies. Newer targeted therapies like Panitumumab,
Zalutumumab, Tyrosine kinase inhibitors such as Erlotinib and
Gefitinib, Dacomitinib, Lapatinib, and injectable drugs like Inlyta
and Axitinib, are making strides in addressing these challenges.
However, specialty pharmacies like Humana Specialty Pharmacy,
Accredo, CVS Specialty, and Optum Specialty Pharmacy, play a
crucial role in ensuring patient access to these treatments.
Surgeries remain a common treatment for oral cavity, pharynx,
paranasal sinuses, and nasal cavity cancers. Nonsurgical
therapeutics, including immunosuppression drugs, are also gaining
popularity. Merck/Debiopharm's Xevinapant, Tipifarnib, Tiragolumab,
Tecentriq, Rozlytrek, and immunotherapies like Pembrolizumab,
Nivolumab, and Dostarlimab, offer hope for patients. However, side
effects like hair loss, speech difficulties, and diminished natural
voice, as well as disease consciousness, remain concerns. The
Cancer Research Institute continues to explore new treatments to
mitigate these challenges.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This head and neck cancer treatment market report extensively
covers market segmentation by
- Route Of Administration
- Therapy
- 2.1 Immunotherapy
- 2.2 Targeted therapy
- 2.3 Chemotherapy
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Injectable- Immunotherapy, which includes
monoclonal antibodies, vaccines, and immune checkpoint inhibitors,
is a promising approach in the global head and neck cancer
treatment market. Immunotherapy enhances the body's immune system
to specifically target cancer cells. For instance, immune
checkpoint inhibitors, such as pembrolizumab and nivolumab, block
the interaction between cancer cells and immune cells, enabling the
immune system to attack the cancer cells. Clinical trials have
shown significant improvement in survival rates and quality of life
for head and neck cancer patients, particularly those with advanced
stages of the disease. Another example is therapeutic vaccines,
like Cemiplimab, designed to stimulate the immune system to
recognize and destroy cancer cells. Monoclonal antibodies, such as
cetuximab, target specific proteins in cancer cells and trigger an
immune response. The favorable safety profile and efficacy of
immunotherapy make it an attractive option for patients, driving
its increasing adoption in the global head and neck cancer
treatment market. The rise in demand for immunotherapy is expected
to propel market growth during the forecast period.
For more information on market segmentation with
geographical analysis including forecast (2024-2028) and historic
data (2017-2021) - Download a Sample Report
Research Analysis
Head and neck cancer refers to malignant tumors that develop in
the throat, nose, mouth, salivary glands, and larynx. Treatment
options include chemotherapy, therapies, and surgical intervention.
Alcohol consumption is a known risk factor for head and neck
cancers. Outpatient visits are essential for regular check-ups and
monitoring progress. Systemic drug therapies, such as tipifarnib, a
Farnesyltransferase Inhibitor, and tiragolumab, an anti-TIGIT
monoclonal antibody, are nonsurgical therapeutics used in the
treatment of advanced or metastatic head and neck cancers.
Immunosuppressive agents may be used to manage side effects of
treatment. The product pipeline includes Merck/Debiopharm's
Xevinapant, a selective X-linked inhibitor of apoptosis (XIAP)
antagonist, and other promising therapies like Tecentriq
(atezolizumab) and Rozlytrek (entrectinib). Immunosuppression may
be necessary during treatment to prevent rejection of transplanted
tissue in surgical cases.
Market Research Overview
Head and neck cancer refers to malignant tumors that develop in
the throat, nose, mouth, salivary glands, larynx, and other areas
in the head and neck region. Risk factors include alcohol
consumption, tobacco use, and certain drugs. The biopharmaceutical
industry is developing various pipeline drugs such as Atezolizumab,
Afatinib, Ipilimumab, Tipifarnib, Tiragolumab, and others for the
treatment of head and neck cancers. Immunotherapy and targeted
therapy are popular treatment types, with PD-L1 inhibitors like
Nivolumab, Opdivo, and Pembrolizumab, and EGFR monoclancer
antibodies like Nimotuzumab, Panitumumab, and Zalutumumab leading
the way. Diagnostic tools play a crucial role in early detection,
while cancer cases continue to rise due to lifestyle factors and
increasing awareness. Sales channels include retail pharmacies,
online pharmacies, and specialty pharmacies like Humana Specialty
Pharmacy, Accredo, CVS Specialty, and Walgreens stores. Treatment
types include systemic drug therapies, nonsurgical therapies, and
surgical treatment. Side effects are a concern with injectable
segment drugs like Inlyta and Axitinib. The pipeline is rich with
potential treatments for various head and neck cancer types,
including those affecting the oral cavity, pharynx, and paranasal
sinuses. Cancer cases continue to rise due to lifestyle factors,
and healthcare expenditure is expected to increase as a result. The
market for head and neck cancer treatment is vast and complex, with
various treatment types, sales channels, and players involved.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Route Of Administration
-
- Therapy
-
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/head-and-neck-cancer-treatment-market-size-is-set-to-grow-by-usd-7-12-billion-from-2024-2028--increasing-incidence-of-head-and-neck-cancers-boost-the-market-technavio-302194641.html
SOURCE Technavio